Substitute for form 1449/PTO

1 of

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete	if Known	
Application Number	10/530,061	
Filing Date	April 4, 2005	
First Named Inventor	John SIDNEY	
Art Unit	1643	
Examiner Name	BRISTOL, Lynn Anne	
Attorney Docket Number	2473.0330002/EKS/PAC	П

			U.S. PATENT DO			
Examiner Cite		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Number-Kind Code <sup>2 (If Known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appea	
/L.B./	US1	5,753,233	05-19-1998	Bleul et al.		
/L.B./	US2	5,783,567	07-21-1998	Hedley et al.		
/L.B./	US3	2002/0119127 A1	08-29-2002	Sette et al.		
	US4					
	US5					
	US6					
	US7					
	US8					
	US9		1			
	US10					
	US11					
	US12					
	US13					
	US14					
	US15					
	US16					
	US17					
	US18					
	US19					
	US20	1				

	000	Fo	Publication Date	Name of Patentee or	Pages, Columns,	$\overline{}$
xaminer	Cite No.1	Foreign Patent Document	MM-DD-YYYY	Applicant of Cited Document	Lines, Where	
nitials*	No.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	т
/L.B./	FP1	WO 91/18294	11-28-1991	Medscand AB		
1	FP2	WO 93/22338	11-11-1993	Rijksuniversiteit te Leiden		
	FP3	WO 99/45954	09-16-1999	Epimmune, Inc.		
	FP4	WO 97/41440	11-06-1997	Rijksuniversiteit te Leiden et al.		Γ
	FP5	EP 0 593 754	04-27-1994	Rijksuniversiteit Leiden et al.		T
	FP6	WO 01/019408	03-22-2001	Zycos Inc.		Г
	FP7	WO 04/011650	02-05-2004	Intercell AG		
	FP8	WO 99/45954	09-16-1999	Epimmune, Inc.		
V	FP9	WO 01/41799	06-14-2001	Epimmune Inc.		Г

Examiner Signature	/Lynn Bristol/	Date Considered	04/26/2010

\*EXAMINES: Initial If reference considered, whether or not clastion is in conformance with MPEP 609. Draw line through clastion if not in conformance and not considered, include copy of this class must intended consumeration to applicate. Applicant's unique clastics designation number (optional) of envisor 6 enviso

This collection of information is required by 3T CFR. 107 and 198. The information is required to obtain or retain a benefit by the pullic which is 16 of 16 and by the USPTO in process) an application. Confidentiality is agreemed by 3S U.S. 1.22 and 3T CFR. 11.4. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual exp. your comments on the amount of time you require to complete this form andrest organized producing this burdner, should be sent to the Chief Information Officer, U.S. Patent and Tradsmark Office, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandris, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete	if Known
Application Number	10/530,061
Filing Date	April 4, 2005
First Named Inventor	John SIDNEY
Art Unit	1643
Examiner Name	BRISTOL, Lynn Anne
Attorney Docket Number	2473.0330002/EKS/PAC

			U.S. PATENT DOG		
Examiner Cite Initials* No.1	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
initials	No.	Number-Kind Code <sup>2 (If Known)</sup>	MM-DD-1111	Applicant of Cited Document	or Relevant Figures Appear
	US1				
	US2				
	US3				
	US4				
	US5				
	US6				
	US7				
	US8				
	US9				
	US10				
	US11				
	US12				
	US13				
	US14				
	US15				
	US16				
	US17				
	US18				
	US19				
	US20				

		Fo	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/L.B./	FP10	WO 01/47541	07-05-2001	Epimmune, Inc.		
						-

1102820\_1.doc /Lvnn Bristol/

Examiner Signature	Date Considered	04/26/2010
-----------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indicated on the year of the reign of the Emperor must proceed the serial number of the patent document by the appropriate symbols as indicated on the document that the document of the patent document symbols are indicated on the document for the patent document symbols as indicated on the document for the patent document symbols. English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case Any comments of bearboard from the amount of time and the state of the Substitute for form 1449/PTO Complete if Known 10/530.061 Application Number INFORMATION DISCLOSURE Filing Date April 4, 2005 First Named Inventor John SIDNEY STATEMENT BY APPLICANT Art Unit 1643 (Use as many sheets as necessary) Examiner Name BRISTOL, Lvnn Anne of Attorney Docket Number 2473.0330002/EKS/PAC Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/L.B./	NPL1	Alexander, M., et al., "Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope," Am. J. Obstet. Gynecol. 175:1586-1593, Mosby-Year Book (1996)	
	NPL2	Bremers, A.J.A., et al., "The Use of Epstein-Barr Virus-Transformed B Lymphocyte Cell Lines in a Peptide-Reconstitution Assay: Identification of CEA-Related H.AA*0301-Restricted Potential Cytotoxic T-Lymphocyte Epitopes," J. Immunother, 18:77-85, Lippincott-Raven (1995)	
	NPL3	Busch, R., et al., "Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces," Int. Immunol. 2:443-451, Oxford University Press (1990)	
	NPL4	Feltkamp, M.C.W., et al., "Vaccination with cytotoxic T lymphocyte epitope- containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells," Eur. J. Immunol. 23:2242-2249, VCH Verlagsgesellschaft (1993)	
	NPL5	Kast, W.M., et al., "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," J. Immunol. 152:3904-3912, American Association of Immunologists (1994)	
	NPL6	Melief, C.J.M., and Kast, W.M., "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General," <i>Cancer Surv. 13</i> :81-99, Cold Spring Harbor Press (1992)	
	NPL7	Rammensee, H-G., et al., "MHC ligands and peptide motifs: first listing," Immunogen. 41:178-228, Springer-Verlag (1995)	
	NPL8	Ressing, M.E., et al., "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*80201-Binding Peptides," J. Immunol. 154:5934-5943, American Association of Immunologists (1995)	
	NPL9	Schulz, M., et al., "Peptide-induced antiviral protection by cytotoxic T cells," Proc. Natl. Acad. Sci. USA 88:991-993, National Academy of Sciences (1991)	
V	NPL10	Sidney, J., et al., "Specificity and Degeneracy in Peptide Binding to HLA-B7- Like Class I Molecules," <i>J. Immunol. 157</i> :3480-3490, American Association of Immunologists (1996)	

Examiner Signature	/Lynn Bristol/	Considered	04/26/2010
-----------------------	----------------	------------	------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. USP I Dis process) an application. Certaindriving a governor of years of the process of the proc

					Equivalent of Form PTO/SB/08b (
Substitute for form	n 1449/PT	0		Con	nplete if Known
				Application Number	10/530,061
INFORMA <sup>*</sup>	TION	DISC	LOSURE	Filing Date	April 4, 2005
STATEME	IFORMATION DISCLOSURE TATEMENT BY APPLICANT	First Named Inventor	John SIDNEY		
			s necessary)	Art Unit	1643
				Examiner Name	BRISTOL, Lynn Anne
Sheet	2	of	2	Attorney Docket Number	2473.0330002/EKS/PAC

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
/L.B./	NPL11	Toes, R.E.M., et al., "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion," Proc. Natl. Acad. Sci. USA 94:14660-14665, National Academy of Sciences (1997)	
/L.B./	NPL12	Geisbell, J., et al., "Detection and characterization of human papillomavirus type 45 DNA in the cervical carcinoma cell line MS751," <i>Journal of General Virology GB 78</i> :655-658, Angewandte Tumorvirologie (1997)	
/L.B./	NPL13	Malik, A., et al., "Identification of a Nonameric H-2K*-Restricted CD8* Cytotoxic T Lymphocyte Epitope on the Plasmodium falciparum Circumsporozoite Protein," Infection and Immunity USA 63: 1955-1959, American Society for Microbiology (1995)	
	NPL14		
	NPL15		
	NPL16		
	NPL17		
	NPL18		
	NPL19		
	NPL20		

1038524 1.DOC Examiner

	Signature	/Lynn Bristol/	Considered	04/26/2010	ı
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and					

Date

<sup>\*</sup>EXAMINER: Initial if reference considered, witeher or not clation is in conformance with MEPP 609. There like through clation if not in conformance and considered, include copy of this form with near communication to applicant or include copy of this form with near communication to applicant is unquie clation designation number (optional). \*Applicant is to place a clock must be rightly interpolary Transition is indeed by the property of the conformance and the